Literature DB >> 15472331

Noninfectious recombinant antigen for detection of St. Louis encephalitis virus-specific antibodies in serum by enzyme-linked immunosorbent assay.

David E Purdy1, Amanda J Noga, Gwong-Jen J Chang.   

Abstract

Proper surveillance of virus activity and a timely response to viral outbreaks depend upon the rapid diagnosis of viral infections. The immunoglobulin M (IgM) antibody-capture enzyme-linked immunosorbent assay (MAC-ELISA) is a fast, sensitive test routinely used for the diagnosis of the medically important West Nile and St. Louis encephalitis flaviviruses. However, the suckling mouse brain-derived (SMB) antigen used in this assay is tedious to prepare and has a risk of exposing personnel to live virus and hazardous chemicals. We report the development of a St. Louis encephalitis virus (SLEV) noninfectious recombinant antigen that is a safe and easily produced alternative antigen for use in diagnostic assays. The expression plasmid pCB8SJ2, containing the premembrane and envelope structural protein-encoding regions of SLEV, was constructed to express secreted extracellular virus-like particles (VLPs) from CHO cells. Blind-coded human serum panels were assembled from patients having recent SLEV, West Nile virus (WNV), Powassan virus, or La Crosse encephalitis virus infections to assess the sensitivity and specificity of assays with SLEV VLP or SMB antigen. MAC-ELISAs with either antigen had comparable sensitivity for the detection of IgM antibodies against SLEV. Importantly, when these two antigens were tested against a human serum panel from patients having recent WNV or Powassan virus infections, the SLEV VLPs were less likely than SMB antigen to detect flavivirus cross-reactive IgM antibodies. An optimized IgG antibody capture ELISA (GAC-ELISA) with both WNV and SLEV VLPs was developed to circumvent the frequently observed higher background in the antigen-capture IgG-ELISA (ACG-ELISA). For the detection of IgG antibodies against WNV, the GAC-ELISA resulted in a statistically significant higher performance accuracy (P = 0.003) than the ACG-ELISA when the WNV VLP antigen was used in both assays. However, no statistical difference was observed in the assay performance of the GAC-ELISA with SLEV VLP or the ACG-ELISA with SLEV SMB antigen.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15472331      PMCID: PMC522323          DOI: 10.1128/JCM.42.10.4709-4717.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  23 in total

Review 1.  The interpretation of diagnostic tests.

Authors:  D E Shapiro
Journal:  Stat Methods Med Res       Date:  1999-06       Impact factor: 3.021

2.  Detection of anti-arboviral immunoglobulin G by using a monoclonal antibody-based capture enzyme-linked immunosorbent assay.

Authors:  A J Johnson; D A Martin; N Karabatsos; J T Roehrig
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

Review 3.  Predicting St. Louis encephalitis virus epidemics: lessons from recent, and not so recent, outbreaks.

Authors:  J F Day
Journal:  Annu Rev Entomol       Date:  2001       Impact factor: 19.686

Review 4.  Flavivirus DNA vaccines: current status and potential.

Authors:  G J Chang; B S Davis; A R Hunt; D A Holmes; G Kuno
Journal:  Ann N Y Acad Sci       Date:  2001-12       Impact factor: 5.691

5.  Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus.

Authors:  Gwong-Jen J Chang; Ann R Hunt; Derek A Holmes; Tracy Springfield; Tzong-Shi Chiueh; John T Roehrig; Duane J Gubler
Journal:  Virology       Date:  2003-02-01       Impact factor: 3.616

6.  Use of immunoglobulin m cross-reactions in differential diagnosis of human flaviviral encephalitis infections in the United States.

Authors:  Denise A Martin; Brad J Biggerstaff; Becky Allen; Alison J Johnson; Robert S Lanciotti; John T Roehrig
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

7.  Standardization of immunoglobulin M capture enzyme-linked immunosorbent assays for routine diagnosis of arboviral infections.

Authors:  D A Martin; D A Muth; T Brown; A J Johnson; N Karabatsos; J T Roehrig
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

8.  A recombinant particulate antigen of Japanese encephalitis virus produced in stably-transformed cells is an effective noninfectious antigen and subunit immunogen.

Authors:  A R Hunt; C B Cropp; G J Chang
Journal:  J Virol Methods       Date:  2001-09       Impact factor: 2.014

9.  A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice.

Authors:  G J Chang; A R Hunt; B Davis
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

10.  West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays.

Authors:  B S Davis; G J Chang; B Cropp; J T Roehrig; D A Martin; C J Mitchell; R Bowen; M L Bunning
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

View more
  13 in total

1.  Development of human-murine chimeric immunoglobulin G for use in the serological detection of human flavivirus and alphavirus antibodies.

Authors:  Brett A Thibodeaux; Amanda N Panella; John T Roehrig
Journal:  Clin Vaccine Immunol       Date:  2010-08-25

2.  Noninfectious virus-like particle antigen for detection of swine vesicular disease virus antibodies in pigs by enzyme-linked immunosorbent assay.

Authors:  Young-Joon Ko; Kang-Seuk Choi; Jin-Ju Nah; David J Paton; Jae-Ku Oem; Ginette Wilsden; Shien-Young Kang; Nam-In Jo; Joo-Ho Lee; Jae-Hong Kim; Hee-Woo Lee; Jong-Myeong Park
Journal:  Clin Diagn Lab Immunol       Date:  2005-08

3.  Comparative analysis of immunoglobulin M (IgM) capture enzyme-linked immunosorbent assay using virus-like particles or virus-infected mouse brain antigens to detect IgM antibody in sera from patients with evident flaviviral infections.

Authors:  Derek A Holmes; David E Purdy; Day-Yu Chao; Amanda J Noga; Gwong-Jen J Chang
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

4.  The C-terminal helical domain of dengue virus precursor membrane protein is involved in virus assembly and entry.

Authors:  Szu-Chia Hsieh; Gang Zou; Wen-Yang Tsai; Min Qing; Gwong-Jen Chang; Pei-Yong Shi; Wei-Kung Wang
Journal:  Virology       Date:  2010-12-03       Impact factor: 3.616

5.  The helical domains of the stem region of dengue virus envelope protein are involved in both virus assembly and entry.

Authors:  Su-Ru Lin; Gang Zou; Szu-Chia Hsieh; Min Qing; Wen-Yang Tsai; Pei-Yong Shi; Wei-Kung Wang
Journal:  J Virol       Date:  2011-03-02       Impact factor: 5.103

6.  The length of and nonhydrophobic residues in the transmembrane domain of dengue virus envelope protein are critical for its retention and assembly in the endoplasmic reticulum.

Authors:  Szu-Chia Hsieh; Wen-Yang Tsai; Wei-Kung Wang
Journal:  J Virol       Date:  2010-02-24       Impact factor: 5.103

7.  Differentiation of West Nile and St. Louis encephalitis virus infections by use of noninfectious virus-like particles with reduced cross-reactivity.

Authors:  Jill A Roberson; Wayne D Crill; Gwong-Jen J Chang
Journal:  J Clin Microbiol       Date:  2007-08-22       Impact factor: 5.948

8.  Development of a human-murine chimeric immunoglobulin M antibody for use in the serological detection of human flavivirus antibodies.

Authors:  Brett A Thibodeaux; John T Roehrig
Journal:  Clin Vaccine Immunol       Date:  2009-03-18

Review 9.  Diagnostic Approach for Arboviral Infections in the United States.

Authors:  Anne Piantadosi; Sanjat Kanjilal
Journal:  J Clin Microbiol       Date:  2020-11-18       Impact factor: 5.948

10.  Characterization of the GXXXG motif in the first transmembrane segment of Japanese encephalitis virus precursor membrane (prM) protein.

Authors:  Ying-Ju Lin; Jia-Guan Peng; Suh-Chin Wu
Journal:  J Biomed Sci       Date:  2010-05-24       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.